The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 136,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Genomics in pharma: telomerase reverse transcriptase (TERT) screening. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s Technology Foresights, which uses over 730,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.
TERT screening is a key innovation area in genomics
TERT gene promoter mutations lead to constitutive activation and expression. This, in turn, leads to replication and proliferation of cancer cells. Mutations in the TERT promoter are found in melanomas, glioblastoma multiforme, hepatocellular carcinoma, bladder cancer, basal cell carcinoma, cutaneous squamous cell carcinoma, and thyroid cancers. Bi-directional Sanger sequencing is performed using PCR primers designed to target mutations in the promoter region of TERT.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 130 companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of TERT screening.
Key players in TERT screening – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
F. Hoffmann-La Roche (Roche) is one of the leading patent filers in TERT screening. Roche is a biotechnology company that develops drugs and diagnostics to treat major diseases. The company offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company has developed several screening methods to identify the mutations in several targets. Immatics and Bio-Techne are some of the other key patent filers in TERT screening.
In terms of application diversity, VitaPath Genetics leads the pack, while GSK and Merck stood in the second and third positions, respectively.
By means of geographic reach, Bio-Techne held the top position, followed by Oxford Biodynamics and Elixirgen.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Genomics.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
